Navigation Links
Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings

SAN FRANCISCO, April 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that positive preclinical and clinical results for its pipeline programs will be presented at numerous medical and scientific meetings over the coming months. These presentations will highlight Nektar's novel therapeutic candidates in the areas of oncology, anti-infectives and central nervous system (CNS), which leverage Nektar's innovative small molecule PEGylation and liquid aerosol platforms.

The data presentations are as follows:

-- April 12-16, 2008: Presentation of Positive Preclinical Data for NKTR-102 (PEG-irinotecan) at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California:

Poster #766: "Enhanced anti-tumor activity of NKTR-102, a novel

PEGylated-irinotecan, when administered in combination with

bevacizumab in a mouse model of human colorectal tumors"

Poster #5741: "NKTR-102, a novel PEGylated-irinotecan, has an

enhanced pharmacokinetic profile with reduced gastrointestinal and

hematopoietic toxicity compared to irinotecan with repeat dosing"

Poster #5742: "NKTR-102, a novel PEGylated-irinotecan, has a

superior acute safety, tolerability, and pharmacokinetic profile

compared to irinotecan"

-- May 8-10, 2008: Presentation of Phase 1 Clinical Trial Multi-Dose Safety Data for NKTR-118 (oral PEG-naloxol) in Opioid Bowel Dysfunction at the American Pain Society (APS) Meeting in Tampa, Florida:

Poster #210: "Results from a phase I, double-blind, randomized,

placebo-controlled, multiple-dose study evaluating the safety,

tolerability, and pharmacokinetics of oral doses of NKTR-118"

-- May 16-21, 2008: Positive Results from Phase 2 Clinical Trials for NKTR-061 (inhaled amikacin) to be presented at the American Thoracic Society (ATS) Meeting in Toronto, Canada:

Poster #516: "NKTR-061 (inhaled amikacin) BID achieves high

epithelial lining fluid concentrations in pneumonic portions of


Poster #517: "Evidence of High Amikacin Lung Deposition in

Mechanically Ventilated Patients (MVP) with Pneumonia and Healthy

Subjects (HS) dosed using NKTR-061"

Poster #518: "High in vivo amikacin lung deposition after NKTR-061

dosing correlates with in vitro aerosol characterization"

-- Positive Phase 1 Clinical data for NKTR-102 (PEG-irinotecan) will also be published at additional oncology conferences this year.

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development technology platforms. Nektar PEGylation and pulmonary technology, expertise, manufacturing capabilities have enabled nine approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements regarding upcoming presentations of preclinical and clinical results at medical and scientific meetings and the potential of Nektar's development technology platforms and product pipeline. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) Nektar's proprietary product candidates and those of certain of its partners are in the early phases of clinical development and pre-clinical development and the risk of failure is high and can unexpectedly occur at any stage, (ii) the timing or success of commencing or concluding clinical trials is subject to a number of uncertainties including but not limited to clinical design, patient enrollment, regulatory requirements and clinical outcomes, (iii) Nektar's or its partners' clinical trials may fail to meet minimum clinical end points, (iv) Nektar or its partners may ultimately fail to obtain regulatory approval of one or more product candidates, (v) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable or sufficiently broad as to protect against competitive products, or intellectual property licenses from third parties may be required in the future, (vi) the outcome of any existing or future intellectual property or other litigation related to Nektar's proprietary product candidates, and (vii) potential competition from existing approved products (branded or generic) or product candidates under development by other companies could negatively impact the commercial potential of Nektar's product candidates due to such competitive factors as efficacy and safety profiles, pricing, and reimbursement by third party payers. These forward-looking statements involve substantial risks and uncertainties, including those risks and uncertainties that are detailed in Nektar's reports and other filings with the SEC including its most recent Annual Report on Form 10-K. Actual results could differ materially from the forward-looking statements contained in this press release. Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events, or otherwise. No information regarding or presented at the medical and scientific meetings referred to above (or contained at the Internet links provided) is intended to be incorporated by reference in this press release.


Tim Warner (650) 283-4915 or

Stephan Herrera (415) 488-7699 or

Jennifer Ruddock (650) 631-4954 or

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
4. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
5. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
6. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
7. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
8. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
9. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
Post Your Comments:
(Date:11/26/2015)... -- Research and Markets ( ) has ... Horizons and Growth Strategies in the Italian Therapeutic ... Forecasts, Competitive Intelligence, Emerging Opportunities" report to ... --> This new 247-page report provides ... monitoring market, including emerging tests, technologies, instrumentation, sales ...
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/25/2015)...  The American Academy of Pediatrics (AAP), American ... March of Dimes cheered today,s signature into law ... of 2015 (S.799), which takes much-needed strides ... to drugs, such as opioids, and to improve ... organizations have worked together leading advocacy efforts for ...
Breaking Medicine Technology:
(Date:11/29/2015)... Jose, CA (PRWEB) , ... November 29, 2015 , ... ... Area, is proud to announce their December, 2015, featured apartment community: Epic. In showcasing ... for corporate housing in the tight Bay Area rental market to efficiently find housing ...
(Date:11/28/2015)... ... ... November 30th at 6:00 a.m. EST until 11:59 p.m. EST, customers will ... to 20% off orders $80 or more to free gifts with purchases, there will be ... a competitive e-commerce website for skin care and cosmetic needs, customers will save on already ...
(Date:11/27/2015)... ... , ... According to an article published November 6th by The ... of British Columbia suggested that laws requiring bicyclists to wear helmets may not actually ... the reason for the controversial conclusion is that, while helmets have certainly prevented a ...
(Date:11/27/2015)... ... November 27, 2015 , ... An inventor, from ... dispense prescription medications at home, so he invented the patent-pending ELECTRONIC M.D. , ... prescription medications. In doing so, it could help to prevent potential overdose situations. ...
(Date:11/27/2015)... ... ... ProSidebar: Fashion is a set of 30 kinetic edge graphics ... editors can easily add an informative sidebar to any FCPX production. Create lists, ... self-animating drop zones, lines, bars, and text with the ease of FCPX's drag and ...
Breaking Medicine News(10 mins):